APPLICATION
ANDA090819
TYPE
ANDA
ORIGINAL APPROVAL
2015-02-19
LATEST ACTION
2025-12-31
ROUTE
SUBLINGUAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
BUPRENORPHINE HYDROCHLORIDEPrescription
BUPRENORPHINE HYDROCHLORIDE EQ 2MG BASE · TABLET · SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDEPrescription
BUPRENORPHINE HYDROCHLORIDE EQ 8MG BASE · TABLET · SUBLINGUAL
Approval history
2025-12-31Labeling · Supplement 38 · standardAP
2025-02-21REMS · Supplement 36AP
2024-03-20REMS · Supplement 29AP
2023-12-15Labeling · Supplement 33 · standardAP
2023-06-14Labeling · Supplement 27 · standardAP
2023-06-14Labeling · Supplement 30 · standardAP
2022-12-16REMS · Supplement 28AP
2022-06-17Labeling · Supplement 26 · standardAP
2022-06-17Labeling · Supplement 24 · standardAP
2022-06-14Labeling · Supplement 23 · standardAP
2022-05-03REMS · Supplement 25AP
2021-03-04Labeling · Supplement 21 · standardAP
2021-02-08Labeling · Supplement 18 · standardAP
2019-10-09Labeling · Supplement 16 · standardAP
2019-09-23Labeling · Supplement 14 · standardAP
2018-10-31REMS · Supplement 15AP
2018-02-01Labeling · Supplement 12 · standardAP
2018-01-31Labeling · Supplement 11 · standardAP
2017-05-23REMS · Supplement 8AP
2016-12-16Labeling · Supplement 6 · standardAP
2016-12-16Labeling · Supplement 5 · standardAP
2016-07-07REMS · Supplement 4AP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.